Michele De Luca has dedicated most of his scientific activities to translational medicine. He is recognised as leading scientist in human squamous epithelial stem cell biology aimed at the development of epithelial stem cell-mediated cell therapy and gene therapy. Michele De Luca and his historic collaborator Graziella Pellegrini, were first to establish human urethral stem cell culture aimed at urethral regeneration in posterior hypospadias. They then developed human limbal stem cell culture for corneal regeneration in patients with severe limbal stem cell deficiency. This treatment leads to recovery of normal vision and is now used worldwide. In February 2015 such cultures were formally approved as an Advanced Therapy Medicinal Product by EMA, which registered them under the name of Holoclar. De Luca and Pellegrini are also pioneering ex-vivo epithelial stem cell-mediated gene therapy for genetic skin diseases. Michele De Luca is internationally recognised for his experience in stem cell therapy and contributed to two reports by the International Society for Stem Cell Research, dealing with new guidelines for responsible translational stem cells research.
Is this you? Claim this profile →
No public contact links on file.
Sectors
Sourcing speakers for your event?
Browse the speaker directory →